Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1618 - The EUROSKI Biomarker Study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia.

Date

09 Sep 2017

Session

Poster display session

Presenters

Sébastien Rinaldetti

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

S. Rinaldetti1, C. Sticht2, M. Pfirrmann3, D. Nowak1, A. Fabarius1, W. Seifarth1, B. Spiess1, P. Panayiotidis4, M. Pagoni5, M. Dimou5, J. Dengler6, C.F. Waller7, T.H. Brümmendorf8, A. Burchert9, G. Freunek10, W. Hofmann1, F. Mahon11, S. Saussele1

Author affiliations

  • 1 Iii. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, 68167 - Mannheim/DE
  • 2 Zentrum Für Medizinische Forschung, Medizinische Fakultät Mannheim, Universität Heidelberg, 68167 - Mannheim/DE
  • 3 Institut Für Medizinische Informationsverarbeitung, Biometrie Und Epidemiologie (ibe), Ludwig-Maximilians-Universität München, Munich/DE
  • 4 Molecular Hematology Laboratory, 1st Department Of Propaedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens/GR
  • 5 Of Hematology, Hellenic Society, Athens/GR
  • 6 Internistische Hämatologie Und Onkologie, Onkologische Praxis Heilbronn,, Heilbronn/DE
  • 7 Klinik Für Innere Medizin I, Universitätsklinikum Freiburg, Freiburg/DE
  • 8 Med. Klinik Iv, Uniklinik RWTH Aachen, Aachen/DE
  • 9 Klinik Für Hämatologie, Onkologie Und Immunologie, Universitätsklinikum Gießen und Marburg, Marburg/DE
  • 10 Medizinisches Versorgungszentrum, Klinikum Straubing,, Straubing/DE
  • 11 Institut Bergonié, University Bordeaux, Bordeaux/FR
More

Resources

Abstract 1618

Background

A substantial proportion of chronic myeloid leukemia (CML) patients in deep molecular response (DMR) reach treatment-free remission (TFR) after tyrosine kinase inhibitors (TKI) cessation. The aim of this study is to identify a gene signature predictive for TFR using whole transcriptome expression analyses.

Methods

RNA from peripheral blood (PB) leukocytes of 60 CML patients who stopped TKI therapy within the EUROSKI study and 10 healthy controls were isolated. CML patients were divided into two groups of whom n = 30 patients had ongoing TFR, while 30 patients encountered molecular recurrence. RNA was isolated at the last day of TKI intake. In order to investigate differentially expressed genes, whole transcriptome arrays (Clariom D, Affymetrix) were analyzed. Candidate biomarkers were tested in multivariate analyses and gene set enrichment analyses (GSEA).

Results

CML patients in DMR compared to healthy controls showed 16000 differentially expressed genes (p  8-fold) for CML patients versus healthy controls. Significant enrichment of NFκB mediated TNFα and TGFβ pathways (FDR

Conclusions

CML patients in DMR present a considerable inflammatory gene expression pattern in PB leukocytes in contrast to healthy controls. Alike previous studies, genes involved in immune exhaustion and immune surveillance were differentially expressed between patients with TFR and relapse. The specific inflammatory gene signature of the relapse cohort suggests ‘stemness’ as third mechanism and driver for relapse.

Clinical trial identification

Legal entity responsible for the study

University Heidelberg

Funding

ELN Foundation

Disclosure

R. Sébastien: Novartis research fund. S. Saussele: Advisory board: Novartis, Bristol-Myers Squib, Pfizer and ARIAD Fees: Novartis, Bristol-Myers Squib, Pfizer and ARIAD Research grant: Novartis and Bristol-Myers Squib Travel grant: Novartis and Bristol-Myers Squib. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.